KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Nektar Therapeutics (NKTR) over the last 13 years, with Q3 2025 value amounting to $18.9 million.

  • Nektar Therapeutics' Shares Outstanding (Diluted Average) rose 3581.91% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 3581.91%. This contributed to the annual value of $205.7 million for FY2024, which is 824.21% up from last year.
  • Nektar Therapeutics' Shares Outstanding (Diluted Average) amounted to $18.9 million in Q3 2025, which was up 3581.91% from $14.1 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Shares Outstanding (Diluted Average) peaked at $210.9 million during Q1 2025, and registered a low of $13.9 million during Q2 2024.
  • Over the past 5 years, Nektar Therapeutics' median Shares Outstanding (Diluted Average) value was $186.8 million (recorded in 2022), while the average stood at $153.2 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Shares Outstanding (Diluted Average) plummeted by 9267.36% in 2024, and later surged by 3581.91% in 2025.
  • Nektar Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $183.3 million in 2021, then rose by 2.09% to $187.1 million in 2022, then rose by 1.53% to $190.0 million in 2023, then rose by 8.24% to $205.7 million in 2024, then plummeted by 90.79% to $18.9 million in 2025.
  • Its last three reported values are $18.9 million in Q3 2025, $14.1 million for Q2 2025, and $210.9 million during Q1 2025.